ReviewAdvances in immunology2019
Signaling control of antibody isotype switching.
Review in Advances in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Impaired suppressive effect of FoxP3 regulatory T cells on B cells in multiple sclerosis.Journal of neuroinflammation · 2026Article
- DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma.Nature communications · 2026Article
- Impact of in ovo myo-inositol administration on immune modulation in broiler chickens.Frontiers in immunology · 2026Article
- CD154 Restricts Helminth-Induced Macrophage Polarisation and Proliferation While Promoting Tissue Residence.Parasite immunology · 2025Article
- Polysaccharide Adjuvants as Innate Immune Trainers: Bridging Pattern Recognition Receptor (PRR) Activation and Metabolic Reprogramming for Synthetic Vaccine Design.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Clinical and experimental treatment of primary humoral immunodeficiencies.Clinical and experimental immunology · 2024Review
- Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas.Haematologica · 2024Article
- Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies.Biomedical journal · 2024Review
- Hepatitis C virus modified sE2Journal of virology · 2024Article
- A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus.Frontiers in immunology · 2024Article
- Immunodysregulatory potentials of polyethylene or polytetrafluorethylene microplastics to mice subacutely exposed via intragastric intubation.Toxicological research · 2023Article
- AFF3, a susceptibility factor for autoimmune diseases, is a molecular facilitator of immunoglobulin class switch recombination.Science advances · 2022Article
- Anti-Microorganisms · 2022Review
- Core Fucosylation Regulates the Function of Pre-BCR, BCR and IgG in Humoral Immunity.Frontiers in immunology · 2022Review
- Designing spatial and temporal control of vaccine responses.Nature reviews. Materials · 2022Review
- Review
- How the Signaling Crosstalk of B Cell Receptor (BCR) and Co-Receptors Regulates Antibody Class Switch Recombination: A New Perspective of Checkpoints of BCR Signaling.Frontiers in immunology · 2021Review
- Long-Range Control of Class Switch Recombination by Transcriptional Regulatory Elements.Frontiers in immunology · 2021Review
- TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Class switch recombination (CSR) generates isotype-switched antibodies with distinct effector functions essential for mediating effective humoral immunity. CSR is catalyzed by activation-induced deaminase (AID) that initiates DNA lesions in the evolutionarily conserved switch (S) regions at the immunoglobulin heavy chain (Igh) locus. AID-initiated DNA lesions are subsequently converted into DNA double stranded breaks (DSBs) in the S regions of Igh locus, repaired by non-homologous end-joining to effect CSR in mammalian B lymphocytes. While molecular mechanisms of CSR are well characterized, it remains less well understood how upstream signaling pathways regulate AID expression and CSR. B lymphocytes express multiple receptors including the B cell antigen receptor (BCR) and co-receptors (e.g., CD40). These receptors may share common signaling pathways or may use distinct signaling elements to regulate CSR. Here, we discuss how signals emanating from different receptors positively or negatively regulate AID expression and CSR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.